DRUG APPROVED FOR CANINE ALZHEIMER'S
By Adnews Staff
The Canadian Bureau of Veterinary Drugs has given its approval to a medication designed to combat a canine condition similar to human Alzheimer's Disease. The drug, called Anipryl, is designed to combat Canine Cognitive Dysfunction, a condition that shows up in older dogs. Signs of the condition include: lethargy, loss of house training, an inability to recognize familiar places or faces, compulsive behavior, or failure to respond to a command. The drug, which had previously been approved for the treatment of Canine Cushing's Disease, is available from veterinarians across Canada. The Canadian distributor of the drug is Draxis Health Inc. of Mississauga, Ont. Print advertising for Anipryl will appear in selected markets. The ads were prepared by Media Focus Group Inc. of Toronto. Veritas Communications Inc., also of Toronto, is handling PR.